Insider transactions

Lloyd Mitchell Segal

CIK 1477123 · PRESIDENT AND CEO · last filed 2026-01-12

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure
$309.4K
Companies
3
Total Filings
38
Lifetime Open-Market Net
-$1.89M

Charts

Trading activity, where the exposure sits, and each trade against the stock price.

RPTX price and trades

Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.

Shares held

Shares owned after each reported transaction on this company (direct holdings as reported).

Open-market buying and selling

by month

Dollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.

Exposure by company

latest
OfficerDirector10% owner* stale (no filing in 3 yrs)

Most recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.

Filer Profile

Reported Address
2150 ST. ELZEAR BLVD. WEST
LAVAL, A8 H7L 4A8
Related Filers
Bausch Health Companies Inc. — 19 joint filings, latest 2013-06-18
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
AKTS Director 19,631 $15.76 $309.4K $0 1 2026-01-12
Repare Therapeutics Inc. (RPTX) Delisted PRESIDENT AND CEO 231,952 $2.65 $614.7K -$1.89M 17 2025-03-14
Bausch Health Companies Inc. (BVF) Delisted Director — — — $0 4 2010-07-07

Recent Filings · Page 2 of 4

38 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2022-01-20 Repare Therapeutics Inc. (RPTX) Delisted Exer (M) — $0 EDGAR
2021-06-30 Repare Therapeutics Inc. (RPTX) Delisted Sell (S) −1,542 -$54.9K EDGAR
2021-06-10 Repare Therapeutics Inc. (RPTX) Delisted Sell (S) −1,576 -$55.2K EDGAR
2021-06-07 Repare Therapeutics Inc. (RPTX) Delisted Mixed −36,000 -$1.27M EDGAR
2021-05-21 Repare Therapeutics Inc. (RPTX) Delisted Sell (S) −3,770 -$132.1K EDGAR
2021-05-20 Repare Therapeutics Inc. (RPTX) Delisted Sell (S) −5,600 -$196.2K EDGAR
2021-04-19 Repare Therapeutics Inc. (RPTX) Delisted Sell (S) −5,512 -$193.0K EDGAR
2021-02-10 Repare Therapeutics Inc. (RPTX) Delisted Grant (A) — $0 EDGAR
2020-06-25 Repare Therapeutics Inc. (RPTX) Delisted Buy (P) +5,000 $100.0K EDGAR
2020-06-19 Repare Therapeutics Inc. (RPTX) Delisted Grant (A) — $0 EDGAR
Showing 11–20 of 38
Page 2 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.